STOCK TITAN

[Form 4] ACHIEVE LIFE SCIENCES, INC. Insider Trading Activity

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Richard Stewart, CEO and Director of Achieve Life Sciences (ACHV), reported settlement of performance restricted stock units and related share sales on 09/18/2025. He received 297,500 shares upon settlement of PRSUs and sold 129,501 shares in multiple transactions for a weighted average price of $2.92 per share to satisfy income tax withholding and remittance obligations. After these transactions the filing shows reported beneficial ownership positions including 358,376 shares (direct) and additional indirect holdings: 359 shares held by spouse and 882 held by Ricanto Limited, of which the reporting person is principal. Two tranches of PRSUs (140,000 and 157,500) remain listed with settlement tied to milestone vesting dates in 2028 and 2029.

Richard Stewart, CEO e Direttore di Achieve Life Sciences (ACHV), ha riportato il perfezionamento delle unità azionarie basate sulle prestazioni (PRSUs) e delle relative vendite di azioni il 18/09/2025. Ha ricevuto 297.500 azioni al perfezionamento dei PRSUs e ha venduto 129.501 azioni in diverse operazioni a un prezzo medio ponderato di $2,92 per azione per soddisfare gli obblighi fiscali sul reddito e i versamenti. Dopo queste operazioni, il deposito mostra posizioni di proprietà beneficiaria tra cui 358.376 azioni (dirette) e ulteriori partecipazioni indirette: 359 azioni detenute dal coniuge e 882 detenute da Ricanto Limited, di cui il soggetto che segnala è principale. Due tranche di PRSUs (140.000 e 157.500) restano elencate con il perfezionamento legato a date di vesting milestone nel 2028 e 2029.

Richard Stewart, CEO y Director de Achieve Life Sciences (ACHV), reportó el acuerdo de acciones restringidas por desempeño (PRSUs) y ventas de acciones relacionadas el 18/09/2025. Recibió 297,500 acciones al liquidarse los PRSUs y vendió 129,501 acciones en múltiples transacciones a un precio promedio ponderado de $2.92 por acción para satisfacer obligaciones de impuestos sobre la renta y remesas. Después de estas operaciones, la presentación muestra posiciones de propiedad beneficiaria que incluyen 358,376 acciones (directas) y participaciones indirectas adicionales: 359 acciones en poder del cónyuge y 882 en Ricanto Limited, de las cuales la persona informante es la principal. Dos tramos de PRSUs (140,000 y 157,500) siguen listados con el ajuste condicionado a fechas de vesting de hitos en 2028 y 2029.

리처드 스튜어트(Richard Stewart), Achieve Life Sciences(ACHV) CEO 겸 이사, 2025년 9월 18일에 성과 기반 주식 보상(PRSU) 정산 및 관련 주식 매각을 보고했습니다. 그는 PRSU 정산으로 297,500주를 받았고, 소득세 원천징수 및 송금 의무를 이행하기 위해 여러 거래에서 129,501주를 매도했으며 주당 가중평균가 미화 2.92달러를 기록했습니다.

Richard Stewart, PDG et Administrateur d'Achieve Life Sciences (ACHV), a fait état du règlement d'unités d'actions restreintes liées à la performance (PRSUs) et des ventes d'actions associées le 18/09/2025. Il a reçu 297 500 actions lors du règlement des PRSUs et a vendu 129 501 actions lors de multiples transactions à un prix moyen pondéré de 2,92 $ par action pour satisfaire les obligations de retenue et de versement d'impôt sur le revenu. Après ces transactions, le dossier indique des positions de propriété bénéficiaire comprenant 358 376 actions (directes) et des participations indirectes supplémentaires : 359 actions détenues par le conjoint et 882 détenues par Ricanto Limited, dont la personne déclarante est principal. Deux tranches de PRSUs (140 000 et 157 500) restent listées avec le règlement lié à des jalons de vesting prévus en 2028 et 2029.

Richard Stewart, CEO und Direktor von Achieve Life Sciences (ACHV), meldete am 18.09.2025 die Abrechnung von leistungsbasierten Restricted Stock Units (PRSUs) und zugehörigen Aktienverkäufen. Er erhielt 297.500 Aktien bei der Abrechnung der PRSUs und verkaufte 129.501 Aktien in mehreren Transaktionen zu einem gewogenen Durchschnittspreis von 2,92 $ je Aktie, um Einkommensteuerabzüge und Überweisungsverpflichtungen zu erfüllen. Nach diesen Transaktionen zeigt die Einreichung beneficial ownership-Positionen, einschließlich 358.376 Aktien (direkt) und weiterer indirekter Bestandteile: 359 Aktien im Besitz des Ehepartners und 882 Aktien bei Ricanto Limited, von denen der meldende Beteiligte der Hauptakteur ist. Zwei Tranchen von PRSUs (140.000 und 157.500) bleiben gelistet, wobei die Abrechnung an Meilenstein-Vesting-Daten in 2028 und 2029 gebunden ist.

ريتشارد ستيوارت، الرئيس التنفيذي وعضو مجلس إدارة Achieve Life Sciences (ACHV)، أبلغ عن تسوية وحدات الأسهم المقيدة المرتبطة بالأداء (PRSUs) والبيع المتعلق بالأسهم في 18/09/2025. استلم 297,500 سهماً عند تسوية PRSUs وباع 129,501 سهماً في عدة تعاملات بسعر متوسط مرجّح قدره $2.92 للسهم من أجل تلبية التزامات الضريبة على الدخل والتحويلات. عقب هذه المعاملات، يُظهر الملف الملكية المستفيدة بما في ذلك 358,376 سهماً (مباشرة) ومشاركات غير مباشرة إضافية: 359 سهماً مملوكاً للزوج و 882 سهماً تمتلكها Ricanto Limited، التي يمثل الشخص المُبلغ نفسه رئيسها. تبقى دفعتان من PRSUs (140,000 و157,500) مدونتين مع التسوية المرتبطة بمواعيد vesting رئيسية في 2028 و2029.

Richard Stewart,Achieve Life Sciences(ACHV)CEO兼董事,报告于2025-09-18完成绩效受限股票单位(PRSUs)的结算及相关股票出售。 他在结算PRSUs时获得了297,500股,并在多笔交易中以加权平均价格$2.92每股出售了129,501股,以满足所得税预扣和汇款义务。交易后,披露的受益所有权头寸包括直接持有的358,376股,以及额外的间接持有:359股为配偶持有,882股由Ricanto Limited持有,且披露人是其主要负责人。两批PRSUs(140,000股和157,500股)仍在列示,结算与2028年和2029年的里程碑归属日期绑定。

Positive
  • Settlement of PRSUs increased direct ownership by 297,500 shares, indicating additional vested equity held by the CEO
  • Filing discloses detailed sale price range ($2.83–$3.02) and weighted average ($2.92), providing transparency on the disposition
Negative
  • Sale of 129,501 shares reduced the reporting person's immediate share count and represents a material disposition relative to the transaction size
  • Significant portion of PRSU proceeds used for tax withholding, meaning the transaction was not a pure constructive purchase of new shares

Insights

TL;DR: CEO received a large PRSU settlement and sold a portion to cover tax obligations, increasing reported direct holdings.

The report documents settlement of PRSUs into 297,500 common shares and the sale of 129,501 shares at a weighted average of $2.92 to satisfy withholding. The filing discloses continued contingent PRSU exposure (total 297,500 additional shares tied to milestones with 2028 and 2029 dates). Ownership disclosure shows a meaningful direct holding of 358,376 shares after the transactions and indirect holdings through spouse and Ricanto Limited. For governance, the mix of in-kind settlement and tax-cover sales is typical for equity compensation monetization; the filing is transparent about price range and ownership structure.

TL;DR: Insider net increase in stock position via PRSU settlement; partial disposition was for tax withholding, not an outright investment exit.

The Form 4 shows the reporting person acquired 297,500 shares upon PRSU settlement and sold 129,501 shares across prices ranging from $2.83 to $3.02, with weighted average $2.92. Post-transaction beneficial ownership is reported as 358,376 shares direct plus indirect holdings. Two outstanding PRSU tranches total 297,500 shares subject to milestone vesting through 2029. The transactions are disclosed clearly and include an undertaking to provide detailed per-trade sale prices on request.

Richard Stewart, CEO e Direttore di Achieve Life Sciences (ACHV), ha riportato il perfezionamento delle unità azionarie basate sulle prestazioni (PRSUs) e delle relative vendite di azioni il 18/09/2025. Ha ricevuto 297.500 azioni al perfezionamento dei PRSUs e ha venduto 129.501 azioni in diverse operazioni a un prezzo medio ponderato di $2,92 per azione per soddisfare gli obblighi fiscali sul reddito e i versamenti. Dopo queste operazioni, il deposito mostra posizioni di proprietà beneficiaria tra cui 358.376 azioni (dirette) e ulteriori partecipazioni indirette: 359 azioni detenute dal coniuge e 882 detenute da Ricanto Limited, di cui il soggetto che segnala è principale. Due tranche di PRSUs (140.000 e 157.500) restano elencate con il perfezionamento legato a date di vesting milestone nel 2028 e 2029.

Richard Stewart, CEO y Director de Achieve Life Sciences (ACHV), reportó el acuerdo de acciones restringidas por desempeño (PRSUs) y ventas de acciones relacionadas el 18/09/2025. Recibió 297,500 acciones al liquidarse los PRSUs y vendió 129,501 acciones en múltiples transacciones a un precio promedio ponderado de $2.92 por acción para satisfacer obligaciones de impuestos sobre la renta y remesas. Después de estas operaciones, la presentación muestra posiciones de propiedad beneficiaria que incluyen 358,376 acciones (directas) y participaciones indirectas adicionales: 359 acciones en poder del cónyuge y 882 en Ricanto Limited, de las cuales la persona informante es la principal. Dos tramos de PRSUs (140,000 y 157,500) siguen listados con el ajuste condicionado a fechas de vesting de hitos en 2028 y 2029.

리처드 스튜어트(Richard Stewart), Achieve Life Sciences(ACHV) CEO 겸 이사, 2025년 9월 18일에 성과 기반 주식 보상(PRSU) 정산 및 관련 주식 매각을 보고했습니다. 그는 PRSU 정산으로 297,500주를 받았고, 소득세 원천징수 및 송금 의무를 이행하기 위해 여러 거래에서 129,501주를 매도했으며 주당 가중평균가 미화 2.92달러를 기록했습니다.

Richard Stewart, PDG et Administrateur d'Achieve Life Sciences (ACHV), a fait état du règlement d'unités d'actions restreintes liées à la performance (PRSUs) et des ventes d'actions associées le 18/09/2025. Il a reçu 297 500 actions lors du règlement des PRSUs et a vendu 129 501 actions lors de multiples transactions à un prix moyen pondéré de 2,92 $ par action pour satisfaire les obligations de retenue et de versement d'impôt sur le revenu. Après ces transactions, le dossier indique des positions de propriété bénéficiaire comprenant 358 376 actions (directes) et des participations indirectes supplémentaires : 359 actions détenues par le conjoint et 882 détenues par Ricanto Limited, dont la personne déclarante est principal. Deux tranches de PRSUs (140 000 et 157 500) restent listées avec le règlement lié à des jalons de vesting prévus en 2028 et 2029.

Richard Stewart, CEO und Direktor von Achieve Life Sciences (ACHV), meldete am 18.09.2025 die Abrechnung von leistungsbasierten Restricted Stock Units (PRSUs) und zugehörigen Aktienverkäufen. Er erhielt 297.500 Aktien bei der Abrechnung der PRSUs und verkaufte 129.501 Aktien in mehreren Transaktionen zu einem gewogenen Durchschnittspreis von 2,92 $ je Aktie, um Einkommensteuerabzüge und Überweisungsverpflichtungen zu erfüllen. Nach diesen Transaktionen zeigt die Einreichung beneficial ownership-Positionen, einschließlich 358.376 Aktien (direkt) und weiterer indirekter Bestandteile: 359 Aktien im Besitz des Ehepartners und 882 Aktien bei Ricanto Limited, von denen der meldende Beteiligte der Hauptakteur ist. Zwei Tranchen von PRSUs (140.000 und 157.500) bleiben gelistet, wobei die Abrechnung an Meilenstein-Vesting-Daten in 2028 und 2029 gebunden ist.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Stewart Richard Alistair

(Last) (First) (Middle)
22722 29TH DR SE
SUITE 100

(Street)
BOTHELL WA 98021

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ACHIEVE LIFE SCIENCES, INC. [ ACHV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
09/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/18/2025 M 297,500(1) A $0 358,376 D
Common Stock 09/18/2025 S 129,501(2) D $2.92(3) 228,875 D
Common Stock 359 I By Spouse
Common Stock 882 I By Ricanto Limited(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Performance Restricted Stock Unit (PRSU) (5) 09/18/2025 M 140,000 (6) 01/22/2028 Common Stock 140,000 $0 0 D
Performance Restricted Stock Unit (PRSU) (5) 09/18/2025 M 157,500 (6) 01/13/2029 Common Stock 157,500 $0 0 D
Explanation of Responses:
1. Represents shares of common stock acquired upon settlement of the performance restricted stock units ("PRSUs") listed in Table II.
2. Represents shares of common stock that have been sold by the Reporting Person to satisfy income tax withholding and remittance obligations in connection with the net settlement of the PRSUs.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.83 to $3.02 per share, inclusive. The reporting person hereby undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. The reporting holder is the principal owner of Ricanto Limited.
5. Each PRSU represents a contingent right to receive one share of the issuer's common stock at settlement.
6. Pursuant to the terms of the award agreement governing the PRSU, the total number of shares underlying the PRSU vest on the achievement of one of certain milestones.
/s/ Sandra Thomson as attorney-in-fact for Richard Stewart 09/22/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Richard Stewart (ACHV) report on Form 4?

The report shows settlement of 297,500 shares from PRSUs and sale of 129,501 shares on 09/18/2025.

At what price were shares sold in the Form 4?

Shares were sold in multiple transactions at prices ranging from $2.83 to $3.02, with a weighted average of $2.92.

How many ACHV shares does the reporting person beneficially own after the transactions?

The filing reports 358,376 shares owned directly after the reported transactions, plus indirect holdings of 359 (spouse) and 882 (Ricanto Limited).

Why were some shares sold according to the Form 4?

The filing states 129,501 shares were sold to satisfy income tax withholding and remittance obligations related to the PRSU net settlement.

Are there remaining unvested PRSUs disclosed?

Yes. Two PRSU tranches totaling 297,500 shares remain contingent on milestone vesting, with settlement dates tied to 01/22/2028 and 01/13/2029.
Achieve Life Sciences Inc

NASDAQ:ACHV

ACHV Rankings

ACHV Latest News

ACHV Latest SEC Filings

ACHV Stock Data

151.78M
48.47M
3.81%
61.44%
10.15%
Biotechnology
In Vitro & in Vivo Diagnostic Substances
Link
United States
SEATTLE